Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Post by C10H12N2on Jul 12, 2022 2:39pm
130 Views
Post# 34818738

Bellus Health or Belly Up

Bellus Health or Belly UpIt looks like the Peacock of Pennyland is on the penny circuit trying to explain away the companies pivot to running all Phase 1 studies after 4 years of ranting about starting at Phase 2. It blows the entire narrative about speed to Phase 2 out of the water . They should just revamp their little website and tell the public the truth. They're a smalltime mom and pop operation. They won't be listing on the NASDAQ. They conduct little clinical trials overseas to deflect blame. The Phase 1s being talked about now if moved to Phase 2 will not generate another data readout until likely 2026. Kiss 2023, 2024, and 2025 good-bye . Excuse me, did someone cough? Oh, that's just Chronic Cough knocking at the door of the USA FDA asking when will it ever get it's crack at a billion dollar market cap? That's if the actual data lives up to any of the hype by management for the last 4 years. It's crazy that Chronic Cough remains a Phase 2 question given all that we know about Bellus Health. Moreau loves to talk about Bellus Health as being a true competitor. Algernon will likely go Belly Up before being compared to Bellus Health.
<< Previous
Bullboard Posts
Next >>